Inhibition of Aspergillus fumigatus and its biofilm by Pseudomonas aeruginosa is dependent on the source, phenotype and growth conditions of the bacterium

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Ferreira, Jose A G ^a,b,g   Penner, John C ^a,h   Moss, Richard B ^c   Haagensen, Janus A J ^d   Clemons, Karl V ^a,b   Spormann, Alfred M ^d   Nazik, Hasan ^a,b,e   Cohen, Kevin ^a   Banaei, Niaz ^b   Carolino, Elisabete ^f   Stevens, David A ^a,b  

^a CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Stanford University   (United States)

^e ISTANBUL UNIVERSITY   (Turkey)

^f INSTITUTO POLITÉCNICO DE LISBOA   (Portugal)

^g School of Medicine Faculdade da Saude e Ecologia   (Brazil)

^h GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE I; ELASTASE; FERROUS CHLORIDE; PROTEINASE K; CHLORIDE; FERRIC CHLORIDE; FERRIC ION; IRON;

ARTICLE; ASPERGILLUS FUMIGATUS; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIOPLANKTON; BACTERIUM ISOLATE; BIOFILM; CONIDIUM; CONTROLLED STUDY; ENZYME ACTIVITY; FETUS; FREEZE THAWING; FUNGAL INHIBITION; FUNGAL PHENOMENA AND FUNCTIONS; HEAT; HUMAN; IN VITRO STUDY; LUNG FIBROSIS; MUCUS; NONHUMAN; PHENOTYPE; PHENOTYPIC VARIATION; PSEUDOMONAS AERUGINOSA; CONFOCAL MICROSCOPY; DRUG EFFECTS; FUNGUS SPORE; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; MOLECULAR WEIGHT; PHYSIOLOGY; PLANKTON; TEMPERATURE;

ASPERGILLUS FUMIGATUS; BIOFILMS; CHLORIDES; DEOXYRIBONUCLEASE I; ENDOPEPTIDASE K; FERRIC COMPOUNDS; HUMANS; IRON; MICROBIAL VIABILITY; MICROSCOPY, CONFOCAL; MOLECULAR WEIGHT; PHENOTYPE; PLANKTON; PSEUDOMONAS AERUGINOSA; SPORES, FUNGAL; TEMPERATURE;

EID: 84941966141     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134692     Document Type: Article

References (76)

1. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2012, Cystic Fibrosis Foundation, Bethesda, MD.
2. Williams HD, Davies JC. Basic science for the chest physician: Pseudomonas aeruginosa and the cystic fibrosis airway. Thorax 2012;67:465-467. doi: 10.1136/thoraxjnl-2011-201498 PMID: 22382597
3. Nagano Y, Millar BC, Johnson E, Goldsmith CE, Elborn JS, Rendall J, et al. Fungal infections in patients with cystic fibrosis. Rev Med Microbiol. 2007;18:11-16.
4. Pihet M, Carrere J, Cimon B, Chabasse D, Delhaes L, Symoens F, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis-a review. Med Mycol. 2008;47:387-397. doi: 10.1080/13693780802609604 PMID: 19107638
5. Horré R, Symoens F, Delhaes L, Bouchara JP. Fungal respiratory infections in cystic fibrosis: a growing problem. Med Mycol. 2010;48:S1-S3.
6. Masoud-Landgraf L, Badura A, Eber E, Feierl G, Marth E, Buzina W. Modified culture method detects a high diversity of fungal species in cystic fibrosis patients. Med Mycol. 2014;52:179-186. PMID: 23651180
7. Sabino R, Ferreira JAG, Moss R, Valente J, Veríssimo C, Carolino E, et al. Molecular epidemiology of Aspergillus from cystic fibrosis patients. J Cystic Fibrosis. 2015;14:474-481.
8. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir Care. 2009;54:628-640. PMID: 19393107
9. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol. 2012;10:841-851. doi: 10.1038/nrmicro2907 PMID: 23147702
10. Shih PC, Huang CT. Effects of quorum-sensing deficiency on Pseudomonas aeruginosa biofilm formation and antibiotic resistance. J Antimicrob Chemother. 2002;49:309-314. PMID: 11815572
11. Mowat E, Butcher J, Lang S, Williams C, Ramage G. Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J Med Microbiol. 2007;56:1205-1212. PMID: 17761484
12. Yang L, Haagensen JA, Jelsbak L, Johansen HK, Sternberg C, Høiby N, et al. In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections. J Bacteriol. 2008;190:2767-2776. PMID: 18156255
13. Seidler MJ, Salvenmoser S, Müller FM. Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob Agents Chemother. 2008;52:4130-4136. doi: 10.1128/AAC.00234-08 PMID: 18710910
14. Mowat E, Lang S, Williams C, McCulloch E, Jones B, Ramage G. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J Antimicrob Chemother. 2008;62:1281-1284. doi: 10.1093/jac/dkn402 PMID: 18819968
15. Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol. 2009;44:547-558. doi: 10.1002/ppul.21011 PMID: 19418571
16. Mowat E, Williams C, Jones B, McChlery S, Ramage G. The characteristics of Aspergillus fumigatus mycetoma development: is this a biofilm? Med Mycol. 2009;47:S120-S126. doi: 10.1080/13693780802238834 PMID: 18654926
17. Smyth AR, Hurley MN. Targeting the Pseudomonas aeruginosa biofilm to combat infections in patients with cystic fibrosis. Drugs Fut. 2010;35:1007-1014.
18. Muller FM, Seidler M, Beauvais A. Aspergillus fumigatus biofilms in the clinical setting. Med Mycol. 2011;49:S96-S100. doi: 10.3109/13693786.2010.502190 PMID: 21254964
19. Beaudoin T, La Fayette S, Roussel L, Berube J, Desrosiers M, Nguyen D, et al. The level of p38 α mitogenactivated protein kinase activation in airway epithelial cells determines the onset of innate immune responses to planktonic and biofilm Pseudomonas aeruginosa. J Infect Dis. 2013;207:1544-1555. doi: 10.1093/infdis/jit059 PMID: 23402824
20. Kaur S, Singh S. Biofilm formation by Aspergillus fumigatus. Med Mycol. 2014;52:2-9. doi: 10.3109/13693786.2013.819592 PMID: 23962172
21. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell Microbiol. 2009;11:1034-1043. doi: 10.1111/j.1462-5822.2009.01323.x PMID: 19374653
22. Loussert C, Schmitt C, Prevost MC, Balloy V, Fadel E, Philippe B, et al. In vivo biofilm composition of Aspergillus fumigatus. Cell Microbiol. 2010;12:405-410. doi: 10.1111/j.1462-5822.2009.01409.x PMID: 19889082
23. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003;37:S225-S264. PMID: 12975753
24. Scharf DH, Heinekamp T, Remme N, Hortschansky P, Brakhage AA, Hertweck C. Biosynthesis and function of gliotoxin in Aspergillus fumigatus. Appl Microbiol Biotechnol. 2012;93:467-472. doi: 10. 1007/s00253-011-3689-1 PMID: 22094977
25. Fillaux J, Bremont F, Murris M, Cassaing S, Rittie JL, Tetu L, et al. Assessment of Aspergillus sensitization or persistent carriage as a factor in lung function impairment in cystic fibrosis patients. Scand J Infect Dis. 2012;44:842-847. doi: 10.3109/00365548.2012.695454 PMID: 22831545
26. Speirs JJ, Van Der Ent CK, Beekman JM. Effects of Aspergillus fumigatus colonization on lung function in cystic fibrosis. Curr Opin Pulm Med. 2012;18:632-638. doi: 10.1097/MCP.0b013e328358d50b PMID: 22965276
27. Ramsey KA, Ranganathan S, Park J, Skoric B, Adams AM, Simpson SJ, et al. Early respiratory infection is associated with reduced spirometry in children with cystic fibrosis. Am J Resp Crit Care Med. 2014;190:1111-1116. doi: 10.1164/rccm.201407-1277OC PMID: 25321321
28. De Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011;66:680-685. doi: 10. 1136/thx.2011.161117 PMID: 21680566
29. Nicolai T, Arleth S, Spaeth A, Bertele-Harms RM, Harms HK. Correlation of IgE antibody titer to Aspergillus fumigatus with decreased lung function in cystic fibrosis. Pediat Pulmonol. 1990;8:12-15.
30. Forsyth KD, Hohmann AW, Martin AJ, Bradley J. IgG antibodies to Aspergillus fumigatus in cystic fibrosis: a laboratory correlate of disease activity. Arch Dis Childhood. 1988;63:953-957.
31. Schonheyder H, Jensen T, Hoiby N, Andersen P, Koch C. Frequency of Aspergillus fumigatus isolates and antibodies to Aspergillus antigens in cystic fibrosis. Acta Path Microbiol Immunol Scand. 1985;93:105-112.
32. Shoseyov D, Brownlee KG, Conway SP, Kerem E. Aspergillus bronchitis in cystic fibrosis. Chest. 2006;130:222-226. PMID: 16840406
33. Coughlan CA, Chotirmall SH, Renwick J, Hassan T, Low TB, Bergsson G, et al. The effect of Aspergillus fumigatus infection on vitamin D receptor expression in cystic fibrosis. Am J Resp Crit Care Med. 2012;186:99-1007.
34. Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest. 2010;137:171-176. doi: 10. 1378/chest.09-1103 PMID: 19567494
35. Yeldandi V, Laghi F, McCabe MA, Larson R, O'Keefe P, Husain A, et al. Aspergillus and lung transplantation. J Heart Lung Transplant. 1995;14:883-890. PMID: 8800724
36. Tomee JF, Mannes GP, Van Der Bij W, Van Der Werf TS, De Boer WJ, Koeter GH, et al. (1996) Serodiagnosis and monitoring of Aspergillus infections after lung transplantation. Ann Intern Med. 1996;125:197-201. PMID: 8686977
37. Cahill BC, Hibbs JR, Savik K, Juni BA, Dosland BM, Edin-Stibbe C, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997;112:1160-1164. PMID: 9367451
38. Nunley DR, Grgurich W, Iacono AT, Yousem S, Ohori NP, Keenan RJ, et al. Allograft colonization and infections with Pseudomonas in cystic fibrosis lung transplant recipients. Chest. 1998;113:1235-1243. PMID: 9596300
39. Zeglen S, Wojarski J, Wozniak-Grygiel E, Siola M, Jastrzebski D, Kucewicz-Czech E, et al. Frequency of Pseudomonas aeruginosa colonizations/infections in lung transplant recipients. Transplant Proc. 2009;41:3222-3224. doi: 10.1016/j.transproceed.2009.07.063 PMID: 19857715
40. Garantziotis S, Palmer SM. An unwelcome guest: Aspergillus colonization in lung transplantation and its association with bronchiolitis obliterans syndrome. Am J Transplant. 2009;9:1705-1706. doi: 10. 1111/j.1600-6143.2009.02709.x PMID: 19538485
41. Botha P, Archer L, Anderson RL, Lordan J, Dark JH, Corris PA, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation. 2008;85:771-774 doi: 10.1097/TP.0b013e31816651de PMID: 18337673
42. Mangan A. Interactions between some aural aspergillus species and bacteria. J Gen Microbiol. 1969;58:261-266. PMID: 4982824
43. Blyth W, Forey A. The influence of respiratory bacteria and their biochemical fractions on Aspergillus fumigatus. Sabouraudia. 1971;9:273-282. PMID: 5002653
44. Kerr JR, Taylor GW, Rutman A, Høiby N, Cole PJ, Wilson R. Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathology. 1999;52:385-387.
45. Mowat E, Rajendran R, Williams C, McCulloch E, Jones B, Lang S, et al. Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol Lett. 2010;313:96-102. doi: 10.1111/j.1574-6968.2010.02130.x PMID: 20964704
46. Holcombe LJ, McAlester G, Munro CA, Enjalbert B, Brown AJ, Gow NA, et al. Pseudomonas aeruginosa secreted factors impair biofilm development in Candida albicans. Microbiology. 2010;156:1476-1486. doi: 10.1099/mic.0.037549-0 PMID: 20150241
47. Bandara HM, K Cheung BP,Watt RM, Jin LJ, Samaranayake LP. Pseudomonas aeruginosa lipopolysaccharide inhibits Candida albicans hyphae formation and alters gene expression during biofilm development. Mol Oral Microbiol. 2013;28:54-69. doi: 10.1111/omi.12006 PMID: 23194472
48. Penner JC, Ferreira JAG, Secor PR, Sweere J, Clemons KV, Stevens DA, et al. Pseudomonas aeruginosa Pf4 phage is an inhibitor of Aspergillus fumigatus biofilm formation and development. Abstr. 54th Intersci. Conf. Antimicrob. Agents Chemother. Washington, DC, 2014, Abstract no. M-435.
49. Denning DW, Clemons KV, Hanson LH, Stevens DA. Restriction endonuclease analysis of total cellular DNA of Aspergillus fumigatus isolates of geographically and epidemiologically diverse origin. J Infect Dis. 1990;162:1151-1158. PMID: 1977804
50. Denning DW, Stevens DA. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother. 1991;35:1329-1333. PMID: 1929289
51. Sabino R, Veríssimo C, Parada H, Brandão J, Viegas C, Carolino E, et al. Molecular screening of 246 Portuguese Aspergillus isolates among different clinical and environmental sources. Med Mycol. 2014;52:519-529. doi: 10.1093/mmy/myu006 PMID: 24847040
52. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard-second edition. Document M38-A2. 2008. CLSI, Wayne, PA
53. Ferreira JA, Carr JH, Starling CE, De Resende MA, Donlan RM. Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob Agents Chemother. 2009;53:4377-4384. doi: 10.1128/AAC.00316-09 PMID: 19546368
54. Meletiadis J, Mouton JW, Meis JFGM, Bouman BA, Donnelly JP, Verweij PE, et al. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol. 2001;39:3402-3408. PMID: 11526191
55. Moss BJ, Kim Y, Nandakumar MP, Marten MR. Quantifying metabolic activity of filamentous fungi using a colorimetric XTT assay. Biotechnol Prog. 2008;24:780-783. doi: 10.1021/bp070334t PMID: 18386938
56. Pierce CG, Uppuluri P, Tristan AR, Wormley FL, Mowat E, Ramage G, et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nature Protocols. 2008;3:1494-1500. doi: 10.1038/nport.2008.141 PMID: 18772877
57. Waite RD, Rose RS, Rangarajan M, Aduse-Opoku J, Hashim A, Curtis MA. Pseudomonas aeruginosa possesses two putative type I signal peptidases, LepB and PA1303, each with distinct roles in physiology and virulence. J Bacteriol. 2012;194:4521-4536. doi: 10.1128/JB.06678-11 PMID: 22730125
58. Mayer-Hamblett N, Ramsey BW, Kulasekara HD, Wolter DJ, Houston LS, Pope CE, et al. Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis. Clin Infect Dis. 2014;59:624-631. doi: 10.1093/cid/ciu385 PMID: 24863401
59. Penner JC, Ferreira JAG, Martinez M, Chen V, Hsu JL, Clemons KV, et al. Effect of iron chelators on the formation and development of Aspergillus fumigatus biofilm. Abstr. 54th Intersci. Conf. Antimicrob. Agents Chemother. Washington, DC, 2014, Abstract no. M-436.
60. Konings AF, Martin LW, Sharples KJ, Roddam LF, Latham R, Reid DW, et al. Pseudomonas aeruginosa uses multiple pathways to acquire iron during chronic infection in cystic fibrosis lungs. Infect Immun. 2013;81:2697-2704. doi: 10.1128/IAI.00418-13 PMID: 23690396
61. Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, et al. Unique lipid A modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis. J Infect Dis. 2007;196:1088-1092. PMID: 17763333
62. Singh G, Imai J, Clemons KV, Stevens DA. Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob Agents Chemother. 2005;49:1369-1376. PMID: 15793114
63. Clemons KV, Stevens DA. Conventional or molecular measurement of Aspergillus load. Med Mycol. 2009;47:S132-137. doi: 10.1080/13693780802213340 PMID: 18654916
64. Manavathu EK, Vager DL, Vazquez JA. Development and antimicrobial susceptibility studies of in vitro monomicrobial and polymicrobial biofilm models with Aspergillus fumigatus and Pseudomonas aeruginosa. BMC Microbiol. 2014;14:53. doi: 10.1186/1471-2180-14-53 PMID: 24588809
65. Moree WJ, Phelan VV, Wu CH, Bandeira N, Cornett DS, Duggan BM, et al. Interkingdom metabolic transformations captured by microbial imaging mass spectrometry. Proc Natl Acad Sci USA. 2012;109:13811-13816. doi: 10.1073/pnas.1206855109 PMID: 22869730
66. Phelan VV, Moree WJ, Aguilar J, Cornett DS, Koumoutsi A, Noble SM, et al. Impact of a transposon insertion in phzF2 on the specialized metabolite production and interkingdom interactions of Pseudomonas aeruginosa. J Bacteriol. 2014;196:1683-1693. doi: 10.1128/JB.01258-13 PMID: 24532776
67. Perez LR, De Freitas AL, Barth AL. Cystic and non-cystic fibrosis Pseudomonas aeruginosa isolates are not differentiated by the quorum-sensing signaling and biofilm production. Curr Microbiol. 2012;64:81-84. doi: 10.1007/s00284-011-0041-z PMID: 22048161
68. Dekimpe V, Déziel E. Revisiting the quorum-sensing hierarchy in Pseudomonas aeruginosa: the transcriptional regulator RhlR regulates LasR-specific factors. Microbiology. 2009;155:712-723. doi: 10. 1099/mic.0.022764-0 PMID: 19246742
69. Whiley RA, Sheikh NP, Mushtaq N, Hagi-Pavli E, Personne Y, Javaid D, et al. Differential potentiation of the virulence of the Pseudomonas aeruginosa cystic fibrosis Liverpool epidemic strain by oral commensal Streptococci. J Infect Dis. 2014;209:769-780. doi: 10.1093/infdis/jit568 PMID: 24158959
70. Fothergill JL, Walshaw MJ, Winstanley C. Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. Eur Resp J. 2012;40:227-237.
71. Salunkhe P, Smart CHM, Morgan JAW, Panagea S, Walshaw MJ, Hart CA, et al. A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J Bacteriol. 2005;187:4908-4920. PMID: 15995206
72. Pressler T, Frederiksen B, Skov M, Garred P, Koch C, Høiby N. Early rise of anti-pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection - a case control study. J Cyst Fibros. 2006;5:9-15. PMID: 16412706
73. Tramper-Stranders GA, Van Der Ent CK, Molin S, Yang L, Hansen SK, Rau MH, et al. Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates. Clin Microbiol Infect. 2012;18:567-574. doi: 10.1111/j.1469-0691.2011.03627.x PMID: 21883670
74. Li Z, Kosorok MR, Farell PM, Laxova A, West SE, Green CG, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293:581-588. PMID: 15687313
75. Gaspar MC, Couet W, Olivier J-C, Pais AACC, Sousa JJS. Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J Clin Micro Infect Dis. 2013;32:1231-1252
76. Noni M, Katelari A, Dimopoulos G, Kourlaba G, Spoulou V, Alexandrou-Athanassoulis H, et al. Inhaled corticosteroids and Aspergillus fumigatus isolation in cystic fibrosis. Med Mycol. 2014;52:715-722. doi: 10.1093/mmy/myu038 PMID: 25056962